To further confirm the tumor-promoting function of ITPKB in TMZ-resistant glioma, we examined tumor growth in vivo after treatment with the ITPKB inhibitor GNF362 (Fig. 7j). This evidence concerns the gene ITPKB and central nervous system cancer.